Dataset Information

Changes in internet use and wishes of cancer survivors: A comparison between 2005 and 2017.

ABSTRACT: BACKGROUND:Given the major changes in internet use for health communication, the objective of the current study was to compare the internet use and wishes of cancer survivors between 2005 and 2017. METHODS:The authors drew a sample of 390 patients in 2005 and 539 patients in 2017 who were diagnosed with breast (128 patients in 2005 and 143 patients in 2017), prostate (96 patients in 2005 and 126 patients in 2017), or gynecologic (89 patients in 2005 and 188 patients in 2017) cancer or lymphoma (77 patients in 2005 and 82 patients in 2017) in 4 different hospitals for the periods 2002 through 2004 and 2014 through 2016. These patients were sent a paper-based questionnaire that contained 45 questions regarding demographics and 4 functions of internet use: content, communication, community, and e-health. RESULTS:The response in 2017 (53%) was lower than that in 2005 (75%). Survivors browsed the internet most frequently to search for information regarding cancer shortly after being diagnosed and while waiting for treatment. There was little change noted with regard to the relative importance attached to the various subjects. In 2017, significant increases were evident with regard to finances (+33%), health care insurance (+29%), and genetics and/or heritability (+27%). The wishes expressed in 2005 by patients were realized in part in 2017. CONCLUSIONS:A significant sample of cancer survivors in the Netherlands have indicated that the internet is an important source of information regarding their illness. However, little change was evident over the past 15 years with regard to patients' priorities regarding their wishes for internet use. The wishes of users in 2005 were found to accurately reflect the internet use of the majority of patients in 2017. The results of the current study support the belief that health care professionals should expand their online services and tailor them toward the needs and wishes of their patients.

SUBMITTER: van Eenbergen MCHJ

PROVIDER: S-EPMC7004117 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Changes in internet use and wishes of cancer survivors: A comparison between 2005 and 2017.

van Eenbergen Mies C H J MCHJ Vromans Ruben D RD Boll Dorry D Kil Paul J M PJM Vos Caroline M CM Krahmer Emiel J EJ Mols Floortje F van de Poll-Franse Lonneke V LV

Cancer 20191003 2

<h4>Background</h4>Given the major changes in internet use for health communication, the objective of the current study was to compare the internet use and wishes of cancer survivors between 2005 and 2017.<h4>Methods</h4>The authors drew a sample of 390 patients in 2005 and 539 patients in 2017 who were diagnosed with breast (128 patients in 2005 and 143 patients in 2017), prostate (96 patients in 2005 and 126 patients in 2017), or gynecologic (89 patients in 2005 and 188 patients in 2017) cance ...[more]

PMID: 31580497

Similar Datasets

Project description:Abstract Background Palivizumabis a monoclonal antibody for preventionof serious lower respiratory tract infection caused by respiratory syncytial virus (RSV) in high risk children. Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD), prematurity (≤ 35 weeks gestational age), and hemodynamically significant congenital heart disease (CHD). The Canadian Registry of Palivizumab (CARESS) tracks palivizumab utilization in high-risk infants, whatever the indication. The decision to give palivizumab is by individual clinicians, not by the investigators, and is often for conditions not listed in the product monograph. Objectives To describe changes over time in indications for palivizumab prophylaxis in Canadian children using a Registry Database. Design/Methods A prospective, observational registry of infants from 32 sites who received ≥1 dose of palivizumab during the 2005–2016 RSV seasons. Usage by indications is shown in two-year increments (Table 1), omitting 2016–17 when enrollment was limited; focused on those with complex medical disorders (CMD).Year*BPDPrematureCHDCMDTotaln%n%n%n%n2005–0716910.6117874.41499.4885.615842007–093449.3256069.33599.743411.736972009–114548.8326663.254010.590617.551662011–134888.3357261.171012.1107318.458432013–154528.8288656.164212.5116622.651472015–161717.9130360.321810.146921.72161Total20788.81476562.6261811.1413617.523598 *year defined as beginning of RSV season in one year to beginning of RSV season in the next year Results 23,598 infants were enrolled, the overall indications for palivizumab were prematurity (62.6%), BPD (8.8%), CHD (11.1%), CMD (17.5%). Comparing groups across the 11 RSV seasons, the percentage with BPD was10.6–8.8%; prematurity decreased from 74.4% to 60.3% and CHD peaked at 12.5% from 2013–15. Palivizumab use in the CMD group rose from 5.6% to 22.6% (2013–15). Total n (%) with specific diagnoses were: Trisomy 21; 942 (21.2), Congenital airway anomalies; 855 (19.2), Neurological disorders; 471 (10.6), Cystic fibrosis; 442 (9.9) other pulmonary; 438 (9.8). The remainder comprised children with multiple indications, or individually less common diseases. Conclusion Caution is required in interpreting these data from a voluntary registry. Nevertheless the off label use of palivizumab in CMD has increased substantially. We suspect this reflects a desire of individual clinicians to protect “fragile” children whenever possible. Clinical Trial Registration: ClinicalTrials.gov NCT00420966

Project description:Abstract Background The Canadian Registry of Palivizumab (CARESS) tracks palivizumab utilization and hospitalizations for respiratory illness (RI) and respiratory syncytial virus (RSVH) in high-risk infants, whatever the indication. The decision to administer palivizumab is taken by individual clinicians at the participating centers. Objectives To provide insight into the current management (utilization, adherence) with palivizumab of children at high risk of RSV infection in the tertiary care centers and community settings through the development of a Canadian Registry Database. A registry may give some indication of safety and effectiveness of an intervention in real life situations in many, uncommon medical conditions. Design/Methods A prospective, observational registry of infants from 32 sites who received ≥1 dose of palivizumab during the 2005–2017 RSV seasons. Palivizumab utilization and RI outcomes were collected monthly over each individual season. Results 25,003 infants were enrolled, the majority were male (56.3%) and Caucasian (68.6%). Subjects were, on average, 5.7 ± 6.4 months old at the time of enrolment, and had a mean gestational age of 32.6 ± 5.0 weeks. Of the children enrolled, indications for palivizumab were prematurity (≤ 35 weeks gestation, 63.3%), chronic lung disease (8.4%), significant congenital heart disease (10.5%), and other complex medical illnesses (17.8%). A total of 109,579 injections were given; average of 4 ± 1 injections per infant. Serious adverse events were uncommon. Adherence was measured in two ways. The number of actual injections compared with the expected and by this measure 83.8% received all of the expected injections. Adherence was also measured based on the length of the inter-injection interval, and by this measure 74.8% were adherent. Over the 12 seasons of CARESS, 1724 children were hospitalized a total of 2054 times. The overall RIH rate was 6.9%, the lowest being in preterm infants (4.3%). 1474 of 1724 children were tested for RSV;334 were RSV-positive. The cumulative RSVH rate was 1.6%. Conclusion The most common indications for palivizumab are prematurity, followed by those with medical complexity. Palivizumab is safe, and given that all of the infants are at high-risk for RSV, an adherence of 74.8% is not unreasonable. The low RSVH (1.6%) rate indicates that palivizumab is effective in the populations in which it is administered. Clinical Trial Registration: ClinicalTrials.gov NCT00420966

Project description:BackgroundThis study aims to investigate growing Internet use in relation to memory and cognition. Though literature reveals human capability to utilize the Internet as a transactive memory source, the formational mechanisms of such transactive memory systems are not extensively explored. The Internet's comparative effects on transactive memory and semantic memory are also relatively unknown.MethodsThis study comprises two experimental memory task survey phases utilizing null hypothesis and standard error tests to assess significance of results.ResultsWhen information is expected to be saved and accessible, recall rates are lower, regardless of explicit instructions to remember (Phase 1, N = 20). Phase 2 suggests the importance of order of attempted recall: depending on whether users first attempt to recall (1) desired information or (2) the information's location, subsequent successful cognitive retrieval is more likely to occur for (1) only desired information or both desired information and location thereof or (2) only desired information's location, respectively (N = 22).ConclusionsThis study yields several theoretical advances in memory research. The notion of information being saved online and accessible in the future negatively affects semantic memory. Phase 2 reveals an adaptive dynamic-(1) as Internet users often have a vague idea of desired information before searching for it on the Internet, first accessing semantic memory serves as an aid for subsequent transactive memory use and (2) if transactive memory access is successful, the need to retrieve desired information from semantic memory is inherently eliminated. By repeatedly defaulting to first accessing semantic memory and then transactive memory or to accessing transactive memory only, Internet users may form and reinforce transactive memory systems with the Internet, or may refrain from enhancing and decrease reliance on transactive memory systems by repeatedly defaulting to access only semantic memory; the formation and permanence of transactive memory systems are subject to users' will. Future research spans the domains of psychology and philosophy.

Project description:BACKGROUND:Evidence supports the benefits of exercise for patients with cancer; however, specific guidance for clinical decision making regarding exercise timing, frequency, duration, and intensity is lacking. Efforts are needed to optimize clinical recommendations for exercise in the cancer population. OBJECTIVES:To aggregate information regarding the benefit of exercise through a systematic review of existing systematic reviews in the cancer exercise literature. DATA SOURCES:PubMed, CINAHL Plus, Scopus, Web of Science, and EMBASE. STUDY ELIGIBILITY CRITERIA:Systematic reviews and meta-analyses of the impact of movement-based exercise on the adult cancer population. METHODS:Two author teams reviewed 302 abstracts for inclusion with 93 selected for full-text review. A total of 53 studies were analyzed. A Measurement Tool to Assess Systematic Reviews (AMSTAR) was used as a quality measure of the reviews. Information was extracted using the PICO format (ie, participants, intervention, comparison, outcomes). Descriptive findings are reported. RESULTS:Mean AMSTAR score = 7.66/11 (±2.04) suggests moderate quality of the systematic reviews. Exercise is beneficial before, during, and after cancer treatment, across all cancer types, and for a variety of cancer-related impairments. Moderate-to-vigorous exercise is the best level of exercise intensity to improve physical function and mitigate cancer-related impairments. Therapeutic exercises are beneficial to manage treatment side effects, may enhance tolerance to cancer treatments, and improve functional outcomes. Supervised exercise yielded superior benefits versus unsupervised. Serious adverse events were not common. LIMITATIONS:Movement-based exercise intervention outcomes are reported. No analysis of pooled effects was calculated across reviews due to significant heterogeneity within the systematic reviews. Findings do not consider exercise in advanced cancers or pediatric populations. CONCLUSIONS:Exercise promotes significant improvements in clinical, functional, and in some populations, survival outcomes and can be recommended regardless of the type of cancer. Although generally safe, patients should be screened and appropriate precautions taken. Efforts to strengthen uniformity in clinical trial reporting, develop clinical practice guidelines, and integrate exercise and rehabilitation services into the cancer delivery system are needed.

Project description:ImportanceAn important consequence of cannabis legalization is the potential increase in the number of cannabis-impaired drivers on roads, which may result in higher rates of traffic-related injuries and fatalities. To date, limited information about the effects of recreational cannabis laws (RCLs) on traffic fatalities is available.ObjectiveTo estimate the extent to which the implementation of RCLs is associated with traffic fatalities in Colorado and Washington State.Design, setting, and participantsThis ecological study used a synthetic control approach to examine the association between RCLs and changes in traffic fatalities in Colorado and Washington State in the post-RCL period (2014-2017). Traffic fatalities data were obtained from the Fatality Analysis Reporting System from January 1, 2005, to December 31, 2017. Data from Colorado and Washington State were compared with synthetic controls. Data were analyzed from January 1, 2005, to December 31, 2017.Main outcome(s) and measuresThe primary outcome was the rate of traffic fatalities. Sensitivity analyses were performed (1) excluding neighboring states, (2) excluding states without medical cannabis laws (MCLs), and (3) using the enactment date of RCLs to define pre-RCL and post-RCL periods instead of the effective date.ResultsImplementation of RCLs was associated with increases in traffic fatalities in Colorado but not in Washington State. The difference between Colorado and its synthetic control in the post-RCL period was 1.46 deaths per 1 billion vehicle miles traveled (VMT) per year (an estimated equivalent of 75 excess fatalities per year; probability = 0.047). The difference between Washington State and its synthetic control was 0.08 deaths per 1 billion VMT per year (probability = 0.674). Results were robust in most sensitivity analyses. The difference between Colorado and synthetic Colorado was 1.84 fatalities per 1 billion VMT per year (94 excess deaths per year; probability = 0.055) after excluding neighboring states and 2.16 fatalities per 1 billion VMT per year (111 excess deaths per year; probability = 0.063) after excluding states without MCLs. The effect was smaller when using the enactment date (24 excess deaths per year; probability = 0.116).Conclusions and relevanceThis study found evidence of an increase in traffic fatalities after the implementation of RCLs in Colorado but not in Washington State. Differences in how RCLs were implemented (eg, density of recreational cannabis stores), out-of-state cannabis tourism, and local factors may explain the different results. These findings highlight the importance of RCLs as a factor that may increase traffic fatalities and call for the identification of policies and enforcement strategies that can help prevent unintended consequences of cannabis legalization.

Dataset Information

Changes in internet use and wishes of cancer survivors: A comparison between 2005 and 2017.

Publications

Changes in internet use and wishes of cancer survivors: A comparison between 2005 and 2017.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets